Axsome Therapeutics, Inc.
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Christopher L. JacobsHouse · R · NY |
AXSMAxsome Therapeutics, Inc. · Stock |
Purchase $15,001 - $50,000 |
Jul 28, 2022 | Jun 16, 2022 | Filing ↗ |
Whale Activity
- Increased177
- New60
- Held62
- Decreased149
- Closed97
- No prior filing18
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 3.5M | $636.5M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.0M | $370.1M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.0M | $363.7M | decreased |
| Invesco Ltd. | 1.9M | $355.9M | increased |
| FMR LLC | 1.4M | $266.3M | decreased |
| MILLENNIUM MANAGEMENT LLC | 1.3M | $244.0M | increased |
| TWO SIGMA INVESTMENTS, LP | 1.1M | $204.8M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 1.0M | $186.3M | increased |
| UBS Group AG | 849.8K | $156.7M | increased |
| STATE STREET CORP | 823.3K | $151.8M | increased |
| Deep Track Capital, LP | 800.0K | $147.5M | increased |
| BANK OF AMERICA CORP /DE/ | 740.7K | $136.6M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Jacobson Mark L.Chief Operating Officer | Sale | −10.0K | $208.65 | $2.1M | Sep 3, 2026 | Form 4 ↗ |
| Jacobson Mark L.Chief Operating Officer | Option exercise | +10.0K | $12.95 | $130K | Sep 3, 2026 | Form 4 ↗ |
| TABUTEAU HERRIOTChief Executive Officer · Director · 10% owner | Sale | −4,660 | $213.95 | $997K | Aug 6, 2026 | Form 4 ↗ |
| TABUTEAU HERRIOTChief Executive Officer · Director · 10% owner | Option exercise | +4,660 | $4.95 | $23K | Aug 6, 2026 | Form 4 ↗ |
| TABUTEAU HERRIOTChief Executive Officer · Director · 10% owner | Sale | −45.0K | $212.01 | $9.5M | Aug 5, 2026 | Form 4 ↗ |
| TABUTEAU HERRIOTChief Executive Officer · Director · 10% owner | Option exercise | +45.0K | $4.95 | $223K | Aug 5, 2026 | Form 4 ↗ |
| TABUTEAU HERRIOTChief Executive Officer · Director · 10% owner | Sale | −49.7K | $240.25 | $11.9M | Jul 1, 2026 | Form 4 ↗ |
| TABUTEAU HERRIOTChief Executive Officer · Director · 10% owner | Option exercise | +49.7K | $4.95 | $246K | Jul 1, 2026 | Form 4 ↗ |
| JEFFS ROGERDirector | Sale | −286 | $249.12 | $71K | Jun 11, 2026 | Form 4 ↗ |
| JEFFS ROGERDirector | Sale | −286 | $246.18 | $70K | Jun 10, 2026 | Form 4 ↗ |
| Mahony SusanDirector | Sale | −300 | $246.18 | $74K | Jun 10, 2026 | Form 4 ↗ |
| Coleman MarkDirector | Sale | −643 | $249.00 | $160K | Jun 10, 2026 | Form 4 ↗ |
| Mahony SusanDirector | Sale | −300 | $237.21 | $71K | Jun 9, 2026 | Form 4 ↗ |
| TABUTEAU HERRIOTChief Executive Officer · Director · 10% owner | Sale | −49.7K | $241.01 | $12.0M | Jun 9, 2026 | Form 4 ↗ |
| TABUTEAU HERRIOTChief Executive Officer · Director · 10% owner | Option exercise | +49.7K | $4.95 | $246K | Jun 9, 2026 | Form 4 ↗ |
| Pizzie NickChief Financial Officer | Sale | −33.0K | $240.09 | $7.9M | Jun 9, 2026 | Form 4 ↗ |
| Pizzie NickChief Financial Officer | Option exercise | +33.0K | $3.50 | $116K | Jun 9, 2026 | Form 4 ↗ |
| JEFFS ROGERDirector | Option exercise | +1,429 | — | — | Jun 8, 2026 | Form 4 ↗ |
| Saad Mark EDirector | Option exercise | +1,429 | — | — | Jun 8, 2026 | Form 4 ↗ |
| Mahony SusanDirector | Option exercise | +1,429 | — | — | Jun 8, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.4M | $339.9M | 0.01% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 1.0M | $245.6M | 0.13% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 578.2K | $141.5M | 0.30% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 495.8K | $121.3M | 0.12% | Jun 30, 2026 |
| VANGUARD EXPLORER FUND | 531.0K | $115.8M | 0.52% | Jul 31, 2026 |
| Invesco Discovery Fund AIM Counselor Series Trust (Invesco Counselor Series Trust) | 535.3K | $106.3M | 1.43% | Aug 31, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund First Trust Exchange-Traded Fund | 426.1K | $104.3M | 3.71% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 409.7K | $85.1M | 0.26% | Apr 30, 2026 |
| iShares Biotechnology ETF iShares Trust | 305.1K | $74.7M | 0.82% | Jun 30, 2026 |
| Franklin Dynatech Fund Franklin Custodian Funds | 300.0K | $73.4M | 0.24% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list AXSM's shares (CUSIP 05464T104), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 2.7M shares5.3%
Jul 27, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming Axsome Therapeutics, Inc. as the client.
Government Contracts
No federal contract awards found for Axsome Therapeutics, Inc..
U.S. Patents
No USPTO patent applications found for Axsome Therapeutics, Inc..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $638.5M | $385.7M | $270.6M | $0 | n/a |
| Operating income | -$166.8M | -$280.6M | -$231.8M | -$179.8M | -$124.7M |
| Net income | -$183.2M | -$287.2M | -$239.2M | -$187.1M | -$130.4M |
| Diluted EPS | -$3.68 | -$5.99 | -$5.27 | -$4.60 | -$3.47 |
| Operating cash flow | -$93.4M | -$128.4M | -$145.1M | -$116.5M | -$108.2M |
| Cash and equivalents | $322.9M | $315.4M | $386.2M | $200.8M | $86.5M |
| Total assets | $689.8M | $568.5M | $588.2M | $331.5M | $87.8M |
| Total liabilities | $601.5M | $511.5M | $397.3M | $221.9M | $72.2M |
| Shareholders' equity | $88.3M | $57.0M | $191.0M | $109.6M | $15.6M |
As Axsome Therapeutics, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 23, 2026 ↗
Stock Splits
No stock splits in AXSM's price history.
Material Events (8-K)
- 8-K · Items 2.02, 8.01, 9.01Results of operations · Other eventsNov 2, 2026
EDGAR ↗ - 8-K · Items 2.02, 8.01, 9.01Results of operations · Other eventsAug 10, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJul 15, 2026
EDGAR ↗ - 8-K · Items 5.02, 9.01Officer / director changeJun 9, 2026
EDGAR ↗ - 8-K · Items 5.07, 9.01Shareholder voteJun 9, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJun 3, 2026
EDGAR ↗ - 8-K · Items 2.02, 8.01, 9.01Results of operations · Other eventsMay 4, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsDec 31, 2025
EDGAR ↗

